查詢結果分析
相關文獻
- 動物模式評估丹參、柴胡舒肝散單獨使用或與斥消靈合用之抗肝纖維化療效
- 肝纖維化動物模式評估中西醫藥併用抗肝纖維化療效及機制探討
- 龍膽瀉肝湯變方對Dimethylnitrosamine誘發大鼠肝損傷的療效探討
- Effects of Mangosteen on α-SMA Expression in HSC-T6 Cells and Liver Fibrosis in Rats
- 益氣活血方藥對HSC膠原表達的抑制作用
- 中醫治療肝纖維化的研究概況
- 中醫傳統方劑--柴胡疏肝散變方於四氯化碳誘導大鼠肝纖維化動物模式探討抑制肝纖維化之療效
- 複方中藥在肝硬化鼠的療效研究
- 中藥蓮子心在肝硬化鼠的療效研究
- 肝纖維化動物模式研究傳統中醫方劑於保肝與抗肝纖維化之作用機制研究和療效評估
頁籤選單縮合
題名 | 動物模式評估丹參、柴胡舒肝散單獨使用或與斥消靈合用之抗肝纖維化療效=Anti-liver Fibrotic Effect of Salvia Miltiorrhiza and Shugan-Huayu Powder Combining with or without Rapamycin in Animal Models |
---|---|
作者姓名(中文) | 程景章; 李儼峰; 林雲蓮; 吳龍源; 吳明儒; 林乃女; 董光中; 邱雲棕; | 書刊名 | 臺灣獸醫學雜誌 |
卷期 | 36:2 2010.06[民99.06] |
頁次 | 頁141-154 |
分類號 | 418.1 |
關鍵詞 | 肝纖維化; 中西醫藥合併; 肝星狀細胞; 動物模式; Liver fibrosis; Traditional Chinese herb; Hepatic stellate cell; Animal model; |
語文 | 中文(Chinese) |
中文摘要 | 利用四氯化碳肝纖維化模式評估中藥-丹參、柴胡舒肝散、西藥-斥消靈及中西藥合併之抗肝纖維化療效,並探究其臨床副作用。實驗分為正常對照、四氯化碳組(CCl4)、丹參(SM 40 mg/kg/day)、柴胡舒肝散(SHP 2.5g/kg/day)、斥消靈(Rapa 1.5mg/kg/day)及Rapa+SM與SHP+Rapa中西藥合併組。臨床發現Rapa與Rapa+SM組出現明顯食慾降低、體重減少和虛弱營養不良副作用,且Rapa+SM組死亡率高達50%。在肝功能(AST、ALT)、肝纖維化程度及肝臟總膠原蛋白含量測定中,Rapa、Rapa+SM、SHP及Rapa+SHP組明顯比CCl4組低(<0.01)。以西方墨點法定量活化態肝星狀細胞含量,SHP、Rapa與Rapa+SM組活化態星狀細胞表現明顯低於CCl4組(P<0.05)。而Rapa、Rapa+SM及Rapa+SHP組之MMP-2,9活性表現均可見減少的趨勢(P<0.001)。由本實驗可推論:複方-柴胡舒肝散之抗肝纖維化療效比單方-丹參明顯,與西藥-斥消靈效果比較則無差異,但在臨床副作用反應上,西藥或合併單方中藥之副作用明顯比西藥合併複方中藥嚴重,此現象可提供臨床上中西藥合併治療及未來研究之參考。 |
英文摘要 | In this study, a rat model of liver fibrosis induced by carbon tetrachioride (CCl4) was used to investigate anti-fibrotic effects of Salvia miltiorrhiza (SM) and Shugan-Huayu powder (SHP), either alone or in combination with rapamycin (Rapa). Liver fibrosis was induced by CCl4 (1.0 mL/kg, by gavage) twice a week for 8 weeks. The CCl4-induced rats were randomly assigned to seven groups: control, CCl4, SM (40 mg/kg/day), SHP (2.52 g/kg/day), Rapa (1.5 mg/kg/day), SM+Rapa and SHP+Rapa. Assessment of anti-fibrotic effects includes clinical signs and body weight, serum biochemistry (AST, ALT, and BUN), histological scoring of liver fibrosis, quantitation of hepatic collagens and α-smooth muscle actin (α-SMA), and zymography for matrix metalloproteinases (MMPs) activity. In clinical signs, Rapa and SM+Rapa group rats revealed remarkable bad appetite, decreased body weight and malnutrition; especially, the mortality of SM+Rapa group was 50%. The contents of AST and ALT in Rapa, Rapa+SM, SHP and Rapa+SHP groups were significantly decreased (P<0.01, vs CCl4 group). The histopathological examination, scoring of liver fibrosis and determination of hepatic total collagen were significantly reduced in Rapa, Rapa+SM, SHP and Rapa+SHP groups compared to CCl4 group (P<0.01). α-SMA proteins were markedly reduced in Rapa and Rapa+SM groups (P<0.001, vs CCl4 group). Decreased MMP-2 activity was noticed in Rapa, Rapa+SM, SHP and Rapa+SHP groups. These results showed anti-fibrotic effects of rapamycin, SM+Rapa, SHP and SHP+Rapa in the rat model of liver fibrosis induced by CCl4. However, the toxity and side effect in Rapa, Rapa+SM were more severe than SHP and Rapa+SHP. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。